Cochrane · systematic review · CD003186
Antiplatelet agents and anticoagulants for hypertension
Shantsila, E, Kozieł-Siołkowska, M, Lip, GYH · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
HypertensionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 80%Moderate 0 · 0%High 1 · 20%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Aspirin compared to placebo for adults with hypertension
Population: adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were excluded)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total mortality Aspirin vs placebo | OR 0.97 [0.87, 1.08] | 3 studies · 35794 participants | Low Downgraded: risk of bias, imprecision |
Cardiovascular mortality Aspirin vs placebo | OR 0.98 [0.82, 1.17] | 3 studies · 35794 participants | Low Downgraded: risk of bias, imprecision |
Non‐fatal cardiovascular events Aspirin vs placebo | OR 0.63 [0.45, 0.87] | 1 study · 2540 participants | Low Downgraded: risk of bias |
Major bleedinga Aspirin vs placebo | OR 1.77 [1.34, 2.32] | 2 studies · 21330 participants | High |
All cardiovascular events Aspirin vs placebo | OR 0.86 [0.77, 0.96] | 3 studies · 35794 participants | Low Downgraded: risk of bias, imprecision |